Core Viewpoint - The article discusses the investment by Kangda New Materials in a new project to produce 30,000 tons per year of Polyarylether (PAE), aiming to enhance its position in the high-value segment of the new materials industry [2]. Investment Project Details - The total investment for the PAE project is approximately 645.74 million RMB, with construction costs of 591.94 million RMB, interest during construction of 16.60 million RMB, and working capital of 37.20 million RMB [3]. - The project will be located in Jinpu New District, covering an area of 50,215.14 square meters (about 75.32 acres), with a construction area of 20,338.16 square meters [3]. - The construction period is expected to last 18 months and will include various production facilities for DMP and PAE, with an annual production capacity of 30,000 tons of PAE and 8,050 tons of ortho-cresol as a byproduct [3]. Product and Market Insights - PAE is produced from 2,6-dimethylphenol (DMP) and is a key material for various applications, including solar energy components and automotive parts [4]. - The production methods for PAE include solvent-free, organic solvent, and aqueous media methods, with the homogeneous solution method being the most efficient [4]. - The demand for modified PPO resin is projected to reach 4,926 tons globally by 2025, with major suppliers including SABIC and Mitsubishi Gas [5]. Industry Developments - Nantong Xingchen has recently completed a 50,000 tons/year PPO project and plans to expand to 130,000 tons/year [6]. - Other companies, such as Shandong Xingshun New Materials and Shanghai Jiarong, are also making significant investments in PPO production [8][9]. - Internationally, companies like SABIC and Korean Kolon Industries are expanding their production capacities for modified PPO and related materials to meet the growing demand in data centers and high-performance applications [10][11]. Competitive Landscape - The domestic market for PPO is experiencing structural contradictions, with basic modified PPO production increasing while electronic-grade and functionalized PPO remain in short supply and heavily reliant on imports [13].

Core Viewpoint - The company plans to invest in a new project to enhance its competitive edge in the new materials sector by producing polyarylether (PAE) and related by-products [2] Group 1: Project Details - The company intends to construct a 30,000 tons/year PAE project through its wholly-owned subsidiary, Kangda New Materials Group Dalian Co., Ltd [2] - Upon completion, the project will produce 30,000 tons/year of PAE, with by-products including 8,050 tons/year of ortho-cresol and 31,000 tons/year of the intermediate product 2,6-dimethylphenol (DMP) [2] - The by-product ortho-cresol will serve as a raw material for the company's subsidiary, Dalian Qihua Electronic Grade Epoxy Resin [2]

Group 1 - The company plans to invest in a 30,000 tons/year Polyarylether (PAE) project through its wholly-owned subsidiary, enhancing its competitive edge in the new materials sector [1] - The project aims to extend the industrial chain towards high value-added segments, with an expected production of 30,000 tons/year of PAE, 8,050 tons/year of by-product ortho-cresol, and 31,000 tons/year of intermediate product 2,6-dimethylphenol (DMP) [1] - The by-product ortho-cresol will serve as a raw material for the company's subsidiary, Dalian Qihua Electronic Grade Epoxy Resin [1]

Group 1 - Yunnan Baiyao plans to invest 137 million yuan in the second phase of its oral liquid project to meet growing market demand for its products [1] - Hanma Technology's subsidiary intends to increase capital by 575 million yuan in Shanghai Suoda and transfer 100% of its shares for 485 million yuan [2] - JiaoKong Technology won a contract worth 16.8 million euros for a project in Turkey, expected to be operational by December 2028 [3] Group 2 - Hanhui Technology's shareholder plans to reduce their stake by up to 1.86% [4] - Haisheng Pharmaceutical reported a 32.72% increase in revenue and a 36.89% increase in net profit for 2025 [5] - Oukang Pharmaceutical's net profit for 2025 decreased by 48.21% despite a 7.73% increase in revenue [6] Group 3 - Huaihe Energy expects a net profit of 1.684 to 1.784 billion yuan for 2025, a year-on-year increase of 96.31% to 107.97% [7] - Watson Bio received approval for clinical trials of its varicella vaccine [8] - ShunNa Co. plans to reduce its stake by up to 1% [9] Group 4 - Chutianlong intends to raise up to 760 million yuan through a private placement [10] - Yifang Technology's shareholders plan to reduce their holdings by up to 34,830 shares [12] - Yunjigroup's subsidiary signed an EPC contract worth 1.331 billion yuan [13] Group 5 - Jianghuai Automobile reported a 2.14% decrease in January sales [15] - Lifan Pharmaceutical participated in a national procurement program and aims to be selected for three products [16] - Magu Technology's shareholder plans to reduce their stake by up to 3% [17] Group 6 - Jianghuai Automobile's private placement raised approximately 3.5 billion yuan, with investor Ge Weidong subscribing for 1 billion yuan [18] - Huichuan Technology expects a net profit increase of 16% to 26% for 2025 [19] - Hezhong China reported a 10.24% decrease in January consolidated revenue [20] Group 7 - Zhongjian Technology plans to invest 30 million yuan in a new fund focused on new energy [22] - Kanda New Materials intends to invest 646 million yuan in a new production project [23] - Yuegui Co.'s subsidiary obtained a mining license [25] Group 8 - TBG Technology plans to invest 1.53 billion yuan in a new project [27] - Xiexin Integration stated it currently lacks production capacity in the "space photovoltaic" sector [28] - Shibao Testing's controlling shareholder plans to transfer 8.5% of the company's shares [29] Group 9 - TeBao Bio reported a 31.18% increase in revenue and a 25.39% increase in net profit for 2025 [30] - Guoke Tiancai reported a 14.73% increase in revenue and a 17.94% increase in net profit for 2025 [31] - Miaokelando signed a memorandum with SADAFCO to explore the children's cheese snack market in Saudi Arabia [32] Group 10 - Tangrenshen reported a 25.6% decrease in January sales revenue [33] - Northeast Securities received approval to establish a subsidiary in Hong Kong [34] - Yiyi Co. terminated its asset acquisition plan due to changes in the target company's performance [35] Group 11 - Wushang Group's major shareholder plans to reduce their stake by up to 3% [36] - Weigang Technology's shareholder plans to reduce their stake by up to 2.98% [37] - Yutong Technology plans to acquire 51% of Huayan Technology for 449 million yuan [38] Group 12 - Huasan Pharmaceutical's shareholder plans to reduce their stake by up to 3% [39] - Runbei Hangke's major shareholder plans to reduce their stake by up to 3% [41] - Huada Technology plans to acquire 100% of Huayi Microelectronics for 2.996 billion yuan [42] Group 13 - ST Lifang's stock will resume trading after completing self-inspection work [43]

Group 1 - The company held its 18th meeting of the 6th Board of Directors on February 10, 2026, with all 11 directors present, and the meeting was conducted in accordance with legal and procedural requirements [2][5] - The Board approved the proposal for its wholly-owned subsidiary to invest in a project to construct a production facility for 30,000 tons/year of Polyarylether (PAE) [3][4] Group 2 - The total planned investment for the PAE project is approximately 645.74 million RMB, with construction costs accounting for 591.94 million RMB, interest during construction at 16.60 million RMB, and working capital of 37.20 million RMB [10] - The project will occupy an area of approximately 50,215.14 square meters and is expected to produce 30,000 tons/year of PAE and 8,050 tons/year of by-product ortho-cresol [12] - The project aims to enhance the company's competitive edge in the high-performance polymer materials sector, particularly in applications for new energy vehicles, electronics, and other high-tech industries [14][15] Group 3 - The PAE project is expected to address the tight supply-demand relationship in the domestic market, thereby enhancing the company's supply chain resilience and competitiveness [16] - The project aligns with the company's strategic focus on high-performance polymer materials and aims to achieve import substitution in high-end manufacturing [14][15] - The implementation of the project is currently in the preparatory stage, with no immediate significant impact on the company's financial status or operational results [16]

格隆汇2月10日丨康达新材(002669.SZ)公布，为深化落实康达新材料（集团）股份有限公司在新材料领 域的布局，增强产品结构的差异化竞争力，推动产业链向高附加值环节延伸，公司拟使用全资子公司康 达新材料集团大连有限公司（简称"康达新材（大连）"）投资建设"3万吨/年聚亚芳基醚（PAE）项 目"，项目计划总投资6.46亿元人民币，最终投资金额以项目建设实际投入为准。项目建设内容：3.1万 t/aDMP生产装置、1万t/a沉析聚合法PAE生产装置、2万t/a均相溶液法PAE生产装置、溶剂回收装置、造 粒包装厂房、空分站及公用、辅助、储运设施、行政办公及生活服务设施。 ...

每经头条（nbdtoutiao）——10倍价差刷屏！"外国人来华就医"火了，三位亲历者这样说⋯⋯ 每经AI快讯，康达新材2月10日晚间发布公告称，公司第六届第十八次董事会会议于2026年2月10日在 公司会议室以现场结合通讯表决方式召开。会议审议了《关于全资子公司拟投资建设3万吨/年聚亚芳基 醚（PAE）项目的议案》等文件。 （记者 王晓波） ...